ES2072431T3 - D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores. - Google Patents

D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.

Info

Publication number
ES2072431T3
ES2072431T3 ES90907159T ES90907159T ES2072431T3 ES 2072431 T3 ES2072431 T3 ES 2072431T3 ES 90907159 T ES90907159 T ES 90907159T ES 90907159 T ES90907159 T ES 90907159T ES 2072431 T3 ES2072431 T3 ES 2072431T3
Authority
ES
Spain
Prior art keywords
hydroxamate
aspartic acid
tumors
treatment
viral infections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90907159T
Other languages
English (en)
Spanish (es)
Inventor
Jorge Vila
Nicole Thomasset
Sangsari Farid Hamedi
Jacques Grange
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Institut National de la Sante et de la Recherche Medicale INSERM
Application granted granted Critical
Publication of ES2072431T3 publication Critical patent/ES2072431T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/50Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES90907159T 1989-04-28 1990-04-27 D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores. Expired - Lifetime ES2072431T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8905744A FR2646348A1 (fr) 1989-04-28 1989-04-28 D-aspartique acide-hydroxamate en tant que medicament

Publications (1)

Publication Number Publication Date
ES2072431T3 true ES2072431T3 (es) 1995-07-16

Family

ID=9381297

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90907159T Expired - Lifetime ES2072431T3 (es) 1989-04-28 1990-04-27 D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.

Country Status (11)

Country Link
EP (1) EP0470144B1 (Direct)
JP (1) JPH04506796A (Direct)
AT (1) ATE121935T1 (Direct)
AU (1) AU660916B2 (Direct)
CA (1) CA2050936A1 (Direct)
DE (1) DE69019148T2 (Direct)
DK (1) DK0470144T3 (Direct)
ES (1) ES2072431T3 (Direct)
FR (1) FR2646348A1 (Direct)
OA (1) OA09519A (Direct)
WO (1) WO1990013291A1 (Direct)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705522A (en) * 1995-09-15 1998-01-06 Compagnie De Developpement Aguettant S.A. Compounds having anti-inflammatory and anti-viral activity, compositions of these, alone and in combination with reverse transcriptase inhibitors
KR101740353B1 (ko) 2009-09-29 2017-05-26 가부시키가이샤 시세이도 항산화 조성물

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2600256B1 (fr) * 1986-06-19 1988-09-16 Inst Nat Sante Rech Med Medicament et composition medicamenteuse pour le traitement des tumeurs ainsi que pour le traitement des maladies infectieuses dues aux virus

Also Published As

Publication number Publication date
WO1990013291A1 (fr) 1990-11-15
EP0470144B1 (fr) 1995-05-03
FR2646348A1 (fr) 1990-11-02
FR2646348B1 (Direct) 1994-04-22
OA09519A (fr) 1992-11-15
DE69019148T2 (de) 1995-08-31
AU5657590A (en) 1990-11-29
JPH04506796A (ja) 1992-11-26
CA2050936A1 (fr) 1990-10-29
ATE121935T1 (de) 1995-05-15
DE69019148D1 (de) 1995-06-08
DK0470144T3 (da) 1995-10-02
AU660916B2 (en) 1995-07-13
EP0470144A1 (fr) 1992-02-12

Similar Documents

Publication Publication Date Title
ES2182837T3 (es) Piran-2-onas y 5,6-dihidropiran-2-onas utiles en el tratamiento del sida y de otros retrovirus.
RU94031102A (ru) Сульфамиды в качестве антагонистов эндотелина и способ лечения соответствующих заболеваний
EA200300544A1 (ru) Эффективные противоопухолевые лекарственные средства
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
DE10199020I2 (de) Galanthamin oder dessen Analoge zur Behandlung derAlzheimerschen Krankheit.
ES2051641B1 (es) Procedimientos para la preparacion de compuestos derivados de tiourea.
ES2071484T3 (es) Derivados de 2,4-diaminoquinazolinas para aumentar la actividad antitumoral.
NO307968B1 (no) Pyrazolo- og pyrrolopyridiner og farmasøytisk blanding derav
ATE135363T1 (de) Nucleoside zur verwendung für die therapie
ATE197670T1 (de) Parenterales busulfan zur behandlung von malignen krankheiten
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ATE78696T1 (de) Arzneimittelzubereitung zur behandlung des immunmangels.
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
HU911193D0 (en) Conjugates consisting of difluor-glutaminic acid and pholates as well as antipholates being suitable for treating pneosplastic illnesses
ES8704962A1 (es) Un procedimiento para preparar 1b-d-ribofuranosil, 1-2-4-triazol-3-carboxamida.
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
BG102404A (en) The application of flupirtin for the prevention and treatment of diseases related to impairement of the haematopoeic cellular system
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
DE69010523D1 (de) Kit oder Zusammensetzung zur Vorbeugung oder Behandlung von HIV-1 Infektionen.
ES8801624A1 (es) Procedimiento para preparar disulfuros heterociclicos
BR0007491A (pt) Uso de 3-isoxazolidinonas e ácidos hidroxilâmicospara o tratamento de infecções
ATE69551T1 (de) Zusammensetzung zur behandlung von boesartigen tumoren insbesondere bei tieren.
PT817786E (pt) Acidos tetronicos substituidos uteis para o tratamento do vih e de outros retrovirus

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 470144

Country of ref document: ES